The Paris Stock Exchange takes a breath, the announcement by Johnson & Johnson of a “pause” in its clinical trials on its candidate vaccine against Covid-10 after a patient contracted an unexpected disease putting a brake on the recent bullish streak. This setback is not the first of its kind (see AstraZeneca, which has its trials quickly) and should not […]
Menu